No Data
No Data
Shanghai Pharmaceuticals Holding Co., Ltd's (SHSE:601607) Largest Shareholders Are Individual Investors Who Were Rewarded as Market Cap Surged CN¥4.6b Last Week
Sh Pharma (601607.SH): Alfocalcidol active pharmaceutical ingredient received market application approval
Sh pharma (601607.SH) announced that the company's controlling subsidiary Shanghai Xinyi Wanxiang Pharmaceutical Co., Ltd. (简...
sh pharma (601607.SH) terminated clinical trials and subsequent development of multiple research and development projects.
sh pharma (601607.SH) announced that the company has decided to terminate I020, B006, B007 (non-Huo...
sh pharma (02607.HK): Subsidiary becomes the holder of the marketing authorization for Ammonium Sulfate Oral Solution.
Gelonghui September 24th, sh pharma (02607.HK) announced that its holding subsidiary Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd. (hereinafter referred to as 'Jinzhu') has received the 'Drug Supplementary Application Approval Notice' issued by the National Medical Products Administration (referred to as the 'NMPA') (Notice Number: 2024B02634), changing the holder of the oral solution of sulfobutyl ether sodium to Shanghai Xinyi Jinzhu Pharmaceutical Co., Ltd.
Don't Race Out To Buy Shanghai Pharmaceuticals Holding Co., Ltd (SHSE:601607) Just Because It's Going Ex-Dividend
SH PHARMA: Interim Report 2024
No Data
No Data